A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m2 (Dralitem® vs. Temodal® Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions

2017

Background Temozolomide is an antineoplastic agent of proven efficacy against high-grade gliomas.

Keywords:

References

Citations